Rezo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Rezo Therapeutics's estimated annual revenue is currently $5.1M per year.
- Rezo Therapeutics's estimated revenue per employee is $124,756
Employee Data
- Rezo Therapeutics has 41 Employees.
- Rezo Therapeutics grew their employee count by 37% last year.
Rezo Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Chemistry | Reveal Email/Phone |
Rezo Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Rezo Therapeutics?
Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. \n\nOur Founders and members of the Board are a group of esteemed, world-class scientists from the University of California, San Francisco: Nevan Krogan, Kevan Shokat, Sourav Bandyopadhyay, Natalia Jura, as well as renowned biotech executives George Scangos and Norbert Bischofberger. These leaders bring with them a strong track record of amazing discoveries and scientific breakthroughs, leading to very successful companies and many FDA approved drugs.
keywords:N/A
N/A
Total Funding
41
Number of Employees
$5.1M
Revenue (est)
37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.4M | 41 | -23% | $4.2M |
#2 | $9.4M | 41 | -11% | N/A |
#3 | $6.6M | 41 | 5% | N/A |
#4 | $5.4M | 41 | N/A | N/A |
#5 | $13.6M | 41 | -16% | N/A |